Bringing the very best science and medicine to our best equine friends
November 2017

Kindred Biosciences Announces Third Quarter 2017 Financial Results

San Francisco, CA (November 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2017 and provided updates on its programs. “We continue to look forward to the upcoming approval of our lead product candidates, Mirataz and Zimeta. We expect a slight adjustment to our regulatory timeline but remain excited to transition to a commercial stage company,” stated Richard Chin, M.D., President and CEO of KindredBio. “We are also pleased to announce positive results of the pilot efficacy study of …

Continue Reading